Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets – Implications for quality control and application

• Published in: European journal of pharmaceutical sciences Vol. 166; p. 105940
• Main Authors: Stass, Heino, Just, Sarah, Weimann, Boris, Ince, Ibrahim, Willmann, Stefan, Feleder, Ethel, Freitas, Cecilia, Yerino, Gustavo, Münster, Uwe
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.11.2021
• Subjects: Absorption; Bioavailability; Dissolution; Food effect; Formulation; Absorption; Food effect; Bioavailability; Dissolution; Formulation
• ISSN: 0928-0987; 1879-0720
• DOI: 10.1016/j.ejps.2021.105940

•In vivo exposure to nifurtimox was unaffected by tablet dissolution rate in vitro.•Robust formulation is desirable in real-world treatment settings.•Exposure to nifurtimox was up to 73% greater in the fed than the fasting state.•Dose-adjusted exposure was similar across the clinically relevant dose range.•Linearity of pharmacokinetics was found for single oral doses up to 240 mg. Nifurtimox is approved in Chagas disease and has been used in endemic countries since the 1960s. Nifurtimox, available as a 120 mg tablet, is administered with food typically three times daily, and dose is adjusted for age and bodyweight. Accurately or reproducibly fragmenting the 120 mg tablet for dose adjustment in young children and those with low bodyweight is problematic. Based on the existing tablet formulation, new nifurtimox 30 mg and 120 mg tablets have been developed in a format that can be divided accurately into 15 mg and 60 mg fragments. In adults with chronic Chagas disease, we investigated whether nifurtimox bioavailability is affected by tablet dissolution rate, and whether different diets affect nifurtimox bioavailability. In an open-label, three-period cross-over study (n=36; ClinicalTrials.gov, NCT03350295), patients randomly received three 30 mg tablet formulations (slow, medium, or fast dissolution; a 4 × 30 mg dose of one formulation per period). In an open-label, four-period cross-over study (n=24; ClinicalTrials.gov, NCT03334838) patients randomly fasted or received one of three meal types (high-fat/high-calorie, low-fat, dairy-based) before ingesting nifurtimox (a 4 × 30 mg dose per period). Acceptance criteria for no difference between groups were 90% confidence intervals (CIs) of exposure ratios in the range 0.8–1.25. Nifurtimox bioavailability was unaffected by tablet dissolution kinetics. Ratios of area under the curve at final assessment (AUC(0–tlast) [90% CI]) were: fast/medium dissolution, 1.061 (0.990–1.137); slow/medium dissolution, 0.964 (0.900–1.033); fast/slow dissolution, 1.100 (1.027–1.179). Compared with a fasting state, nifurtimox bioavailability increased by 73% after a high-fat/high-calorie meal (AUC(0–tlast) ratio [90% CI], 1.732 [1.581–1.898]); smaller increases were seen with the other meal types (low-fat: 1.602 [1.462–1.755]; dairy-based: 1.340 [1.222–1.468]). Although type of diet can affect bioavailability, taking nifurtimox with food is most important. [Display omitted]